A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab)

被引：1
|
作者：
Cascinu, S. [1 ]
Lonardi, S. [2 ]
Rosati, G. [3 ]
Nasti, G. [4 ]
Zaniboni, A. [5 ]
Romiti, A. [6 ]
Aglietta, M. [7 ]
Bilancia, D.
Iaffaioli, V. [4 ]
Zagonel, V. [2 ]
Giordano, M. [8 ]
Corsi, D. [9 ]
Ferrau, F. [10 ]
Labianca, R. [11 ]
Berardi, R. [12 ]
Rulli, E. [13 ]
Floriani, I. [13 ]
机构：
[1] Azienda Osped Reg Torrette, Clin Oncol Med, Ancona, Italy
[2] Ist Oncol Veneto, UO Oncol Med, Padua, Italy
[3] Azienda Osped S Carlo, UO Oncol Med, Potenza, Italy
[4] INT IRCCS Fdn Pascale, UO Oncol Med, Naples, Italy
[5] Fdn Poliambulanza, UO Oncol Med, Brescia, Italy
[6] AOU Policlin St Andrea, UO Oncol Med, Rome, Italy
[7] Ist Candiolo IRCCS, UO Oncol Med, Candiolo, TO, Italy
[8] Osped St Anna, UO Oncol Med, Como, Italy
[9] Osped San Pietro Fatebenefratelli, UO Oncol Med, Rome, Italy
[10] Osped San Vincenzo, UO Oncol Med, Taormina, Italy
[11] Osped Papa Giovanni XXIII, UO Oncol Med, Bergamo, Italy
[12] Azienda Osped Reginale Torrette, Clin Oncol Med, Ancona, Italy
[13] Ist Ric Farmacol Mario Negri, Lab Ric Clin, Milan, Italy
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(15)30040-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2006
引用
收藏
页码：S329 / S329
页数：1
相关论文
共 50 条
  • [21] First-line FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC): the open-label, randomized phase 3 TAILOR trial
    Qin, S.
    Xu, J.
    Wang, L.
    Cheng, Y.
    Liu, T.
    Chen, J.
    Eggleton, S. P.
    Liu, J.
    Li, J.
    ANNALS OF ONCOLOGY, 2016, 27 : 141 - 141
  • [22] Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy
    Tsai, Hsiang-Lin
    Chen, Yen-Cheng
    Yin, Tzu-Chieh
    Su, Wei-Chih
    Chen, Po-Jung
    Chang, Tsung-Kun
    Li, Ching-Chun
    Huang, Ching-Wen
    Wang, Jaw-Yuan
    ONCOLOGY RESEARCH, 2021, 29 (01) : 47 - 61
  • [23] Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX plus panitumumab followed by FOLFIRI plus bevacizumab (Sequence 1) versus FOLFOX plus bevacizumab followed by FOLFIRI plus panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left (L)-sided, unresectable colorectal cancer (CRC): The CR-SEQUENCE.
    Salazar, Ramon
    Carrato, Alfredo
    Garcia Garcia, Teresa
    Gallego Plazas, Javier
    Gomez-Espana, Auxiliadora
    Gravalos Castro, Cristina
    Pilar Escudero, M.
    Jose Safont, Maria
    Salud Salvia, Antonieta
    Pericay, Carles
    Grana Suarez, Begona
    Marrupe, David
    Vidal, Rosario
    Losa, Ferran
    Fernandez Rodriguez, Teresa
    Manzano Mozo, Jose Luis
    Tabernero, Josep
    Mansinho, Helder
    Montagut, Clara
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients.
    Shi, Yuankai
    Li, Jin
    Xu, Jianming
    Cheng, Ying
    Liu, Wei
    Cheng, Yigui
    Bai, Li
    Zhang, Yiping
    He, Xiaohui
    Luo, Yi
    Liu, Yunpeng
    Yao, Qiang
    Li, Yuhong
    Qin, Shukui
    Hu, Xiaohua
    Guo, Yajun
    Sun, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial
    Qin, Shukui
    Li, Jin
    Wang, Liwei
    Xu, Jianming
    Cheng, Ying
    Bai, Yuxian
    Li, Wei
    Xu, Nong
    Lin, Li-zhu
    Wu, Qiong
    Li, Yunfeng
    Yang, Jianwei
    Pan, Hongming
    Ouyang, Xuenong
    Qiu, Wensheng
    Wu, Kaichun
    Xiong, Jianping
    Dai, Guanghai
    Liang, Houjie
    Hu, Chunhong
    Zhang, Jun
    Tao, Min
    Yao, Qiang
    Wang, Junyuan
    Chen, Jiongjie
    Eggleton, S. Peter
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (30) : 3031 - +
  • [26] Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial
    Liu, T.
    Li, J.
    Xu, J.
    Wang, L.
    Cheng, Y.
    Chen, W.
    Chen, J.
    Pescott, C. P.
    Qin, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] PANIB 20139173: Randomized, multicentre phase II trial comparing fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus panitumumab versus FOLFOX plus bevacizumab in patients with previously untreated, RAS wild-type (WT) metastatic colorectal cancer (mCRC)
    Janssens, K.
    Fransen, E.
    Rolfo, C. D.
    Lybaert, W.
    Demey, W.
    Decaestecker, J.
    Hendrickx, K.
    Kalantari, H.
    Op de Beeck, K.
    Van Camp, G.
    Peeters, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S440 - S440
  • [28] Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial
    Aranda, E.
    Ia-Alfonso, P. Garc '
    Benavides, M.
    Sanchez-Ruiz, A.
    Guillen-Ponce, C.
    Safont, M. J.
    Alcaide, J.
    Gomez, A.
    Lopez, R.
    Manzano, J. L.
    Mendez-Urena, M.
    Lopez, C.
    Garcia-Paredes, B.
    Gravalos, C.
    Garcia-Garcia, T.
    Falco, E.
    Martin-Valades, J. I.
    Gonzalez-Flores, E.
    Navalon, M.
    Diaz-Rubio, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S371 - S372
  • [29] Phase I study of EMD 525797 (DI17E6), an antibody targeting αυβ integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer.
    Elez, Elena
    Kocakova, Ilona
    Hoehler, Thomas
    Martens, Uwe Marc
    Bokemeyer, Carsten
    Van Cutsem, Eric
    Fram, Robert J.
    Bernard, Laurence
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients
    Pietrantonio, F.
    Lobefaro, R.
    Antista, M.
    Miceli, R.
    Raimondi, A.
    Lonardi, S.
    Rimassa, L.
    Saggio, S.
    Capone, I.
    Farina, G.
    Longarini, R.
    Mosconi, S.
    Bianchi, A. Sartore
    Tomasello, G.
    Petrelli, F.
    Murgioni, S.
    Perrone, F.
    Barault, L.
    Milione, M.
    Di Nicolantonio, F.
    Di Bartolomeo, M.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2019, 30 : 135 - 135
12345